Literature DB >> 9625537

Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-beta gene.

Z Dong1, S H Juang, R Kumar, I Eue, K Xie, D Bielenberg, W Lu, C Bucana, X Yang, I J Fidler.   

Abstract

In this study, we endeavored to determine the effectiveness of interferon beta (IFNbeta) gene therapy against highly metastatic murine UV-2237m fibrosarcoma cells. UV-2237m cells were engineered to produce murine IFNbeta constitutively following infection by a retroviral vector harboring the murine IFNbeta gene. Parental (UV-2237m-P), control-vector-transduced (UV-2237m-Neo), and IFNbeta-transduced (UV-2237m-IFNbeta) cells were injected subcutaneously (s.c.) or intravenously (i.v.) into syngeneic mice. Parental and control-transduced cells produced rapidly growing tumors, whereas IFNbeta-transduced cells did not. The tumorigenicity of IFNbeta-sensitive or -resistant parental cells was significantly suppressed when they were injected s.c. together with IFNbeta-transduced cells. The IFNbeta-transduced cells did not inhibit growth of parental cells injected s.c. at a distant site. UV-2237m-IFNbeta cells produced s.c. tumors in nude, SCID/Beige, and natural killer(NK)-cell-compromised syngeneic mice. The IFNbeta-transduced cells were more sensitive to in vitro splenic cell-mediated lysis than were the parental or control-transduced cells. Pretreatment of C3H/HeN mice with the NK-cell-selective antiserum (anti-asialoGM1) partially abrogated the cytotoxic activity of the cells. Cytotoxic activity was not observed in mixed culture of UV-2237m-IFNbeta cells and splenic cells from SCID/Beige mice. Significant cytotoxicity against UV-2237m-IFNbeta cells was mediated by macrophages activated by either IFNgamma, lipopolysaccharide, or a combination of both. Our data led us to conclude that the constitutive expression of IFNbeta can suppress tumorigenicity and metastasis of UV-2237m cells, which is due, in part, to activation of host effector cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625537     DOI: 10.1007/s002620050472

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  4 in total

1.  Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.

Authors:  H Tada; D J Maron; E A Choi; J Barsoum; H Lei; Q Xie; W Liu; L Ellis; A D Moscioni; J Tazelaar; S Fawell; X Qin; K J Propert; A Davis; D L Fraker; J M Wilson; F R Spitz
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response.

Authors:  C Rozera; D Carlei; P L Lollini; C De Giovanni; P Musiani; E Di Carlo; F Belardelli; M Ferrantini
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

3.  Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.

Authors:  X Q Qin; N Tao; A Dergay; P Moy; S Fawell; A Davis; J M Wilson; J Barsoum
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 4.  Engineered stem cells targeting multiple cell surface receptors in tumors.

Authors:  Sanam L Kavari; Khalid Shah
Journal:  Stem Cells       Date:  2019-08-21       Impact factor: 6.277

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.